Mersana Therapeutics MRSN 深 沪
已收盘 08-15 16:00:00 美东时间
7.16
-0.260
-3.50%
华盛通- 最 高7.44
- 今 开7.44
- 成交量 8.00万股
- 最 低 7.00
- 昨 收 7.42
- 总市值 8.95亿
- 52周最高 70.75
- 市盈率 静 --
- 换手率 0.06%
- 52周最低 5.21
- 委 比 -53.98%
- 总股本 1.25亿
- 历史最高 727.25
- 量 比 0.55
- 振 幅 5.93%
- 历史最低 6.4725
- 每 手 1
- 风险率 19.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅仍有782.74%！Passage BIO遭Canaccord Genuity下调目标价至67美元，维持"买入"评级
今日重点评级关注：Northland Capital Markets：维持BrainsWay"跑赢大市"评级，目标价从15美元升至19美元；Lake Street：维持Hyperfine"买入"评级，目标价从1.5美元升至2美元
08-15 09:30
Guggenheim Maintains Buy on Mersana Therapeutics, Lowers Price Target to $30
Guggenheim analyst Michael Schmidt maintains Mersana Therapeutics (NASDAQ:MRSN) with a Buy and lowers the price target from $125 to $30.
08-14 21:32
Mersana Therapeutics Q2 EPS $(4.87) Misses $(3.93) Estimate, Sales $3.056M Miss $6.363M Estimate
Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(4.87) per share which missed the analyst consensus estimate of $(3.93) by 23.95 percent. This is a 1.81 percent increase over losses of $(4.96) per share
08-13 19:03
Earnings Scheduled For August 13, 2025
Companies Reporting Before The Bell • Evotec (NASDAQ:EVO) is projected to repor...
08-13 16:32
Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results
Mersana Therapeutics updated on their Emi-Le ADC candidate, enrolling over 45 TNBC patients in Phase 1 expansion cohorts, with initial data expected in H2 2025. The company also highlighted advancements in XMT-2056 and achieved a $15M milestone with GSK. Financially, Q2 2025 results showed a net loss of $24.3M, with cash reserves of $77M. A 1-for-25 reverse stock split reduced outstanding shares, and the company remains compliant with Nasdaq's bi...
08-13 11:00
A Look at Mersana Therapeutics's Upcoming Earnings Report
Mersana Therapeutics (NASDAQ:MRSN) will release its quarterly earnings report o...
08-13 02:02
Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025
Mersana Therapeutics plans to release its second-quarter 2025 financial results on August 13, 2025, along with a business update. A conference call and webcast will be held at 8:00 a.m. ET, accessible via 833-255-2826 (domestic) or 412-317-0689 (international). The webcast will be available on Mersana's website (www.mersana.com) with a 90-day replay. Mersana focuses on developing antibody-drug conjugates (ADCs) for cancers with high unmet needs, ...
08-06 12:00
Merus to Present at the Canaccord Genuity 45th Annual Growth Conference
<p>Merus N.V., a biotech company specializing in innovative antibody therapies, has announced that its CEO, Bill Lundberg, M.D., will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025, at 1:30 p.m. ET. The event will be webcast live and archived on the company's Investors page. Merus is focused on developing full-length multispecific antibodies and antibody drug conjugates, which have shown p...
08-06 12:00
Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Merus N.V. granted 240,000 stock options to two new employees on August 1, 2025, as an inducement award outside its 2016 Incentive Award Plan. The options have an exercise price of $65.56 per share, a ten-year term, and vest over four years. The Board of Directors and independent directors approved the grant based on the Compensation Committee’s recommendation. The awards are subject to continuous service and the Plan’s terms.
08-04 20:01
Mersana Therapeutics Announces Reverse Stock Split
Mersana Therapeutics ( ($MRSN) ) just unveiled an update. On July 24, 2025, Mer...
07-24 20:58
